Therapeutic advances for epidermal growth factor receptor non-classical mutations in non-small cell lung cancer after targeted therapy resistance
10.12354/j.issn.1000-8179.2025.20250740
- VernacularTitle:非小细胞肺癌EGFR非经典突变靶向耐药后的治疗进展
- Author:
Ma JILI
1
;
Wang JIAYI
;
Qiao HUI
Author Information
1. 兰州大学第一临床医学院(兰州市 730000)
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer(NSCLC);
epidermal growth factor receptor(EGFR);
non-classical mutations;
treatment strategies
- From:
Chinese Journal of Clinical Oncology
2025;52(16):854-859
- CountryChina
- Language:Chinese
-
Abstract:
The epidermal growth factor receptor(EGFR)is a key oncogenic driver in non-small cell lung cancer(NSCLC),and its mutations have significant clinical implications.While classical mutations,such as exon 19 deletions and exon 21 L858R substitutions,are well estab-lished,increasing attention has shifted toward less common,non-classical EGFR mutation subtypes.The widespread adoption of high-throughput sequencing technologies such as next-generation sequencing(NGS)has substantially improved the detection rate of non-classic-al EGFR mutations.Thus,their molecular characteristics and therapeutic responses have been increasingly elucidated.However,due to their significant heterogeneity,substantial variability exists in the sensitivity of different non-classical mutations to EGFR tyrosine kinase inhibitors(EGFR-TKIs).Furthermore,the scarcity of clinical samples limits the availability of robust evidence.Additionally,prolonged clinical use of EGFR-TKIs can also lead to acquired resistance,further complicating treatment strategies.Despite these challenges,ongoing research continues to explore targeted therapies for patients with non-classical EGFR mutations.This review summarizes recent studies on non-classical EGFR mutations in NSCLC,examines current therapeutic approaches,and outlines clinical recommendations for managing patients after EGFR-TKI treatment failure.By integrating existing evidence and clinical experience,this review aims to optimize individualized treatment strategies for these patients,with the ultimate goal of improving their prognosis and quality of life.
